伏立康唑与奥美拉唑联合应用致伏立康唑超快代谢型患者血药浓度增高的分析

doi:10.19803/j.1672-8629.2020.08.10

中国药物警戒 ›› 2020, Vol. 17 ›› Issue (8): 496-501.
DOI: 10.19803/j.1672-8629.2020.08.10

伏立康唑与奥美拉唑联合应用致伏立康唑超快代谢型患者血药浓度增高的分析

连玉菲¹, 刘洪涛¹, 任炳楠¹, 赵海静¹, 王彦泽², 张玥¹, 田冬冬¹, 曹格溪¹, 岳圆圆¹, 闫莉^1,*

¹河北省人民医院,河北石家庄 050051;
²河北省药品审评认证服务中心,河北石家庄 050000

收稿日期:2020-07-31 修回日期:2020-07-31 出版日期:2020-08-15 发布日期:2020-07-31
通讯作者: ^*闫莉,女,博士,主任医师·硕导,呼吸内科。E-mail：1179339700@qq.com
作者简介:连玉菲,女,硕士,主管药师,临床药理。

Blood Concentration of Voriconazole in Patients with Ultrarapid Metabolism Increased by Combination of Voriconazole and Omeprazole

LIAN Yufei¹, LIU Hongtao¹, REN Bingnan¹, ZHAO Haijing¹, WANG Yanze², ZHANG Yue¹, TIAN Dongdong¹, CAO Gexi¹, YUE Yuanyuan, YAN Li^1,*

¹Hebei General Hospital, Shijiazhuang 050051;
²Hebei Drug Evaluation and Certification Service Center, Shijiazhuang 050000

Received:2020-07-31 Revised:2020-07-31 Online:2020-08-15 Published:2020-07-31
Supported by:
河北省医学科学研究重点课题计划（ZD20180080）：临床药师依托精准医学对药物疗效及不良反应监护研究

摘要/Abstract

摘要： 目的探讨伏立康唑与奥美拉唑钠联合应用对CYP2C19超快代谢型患者提升伏立康唑血药浓度、增强抗真菌疗效的治疗经验。方法分析总结3例伏立康唑相关基因CYP2C19超快代谢型侵袭性肺真菌病患者,依托血药浓度监测,设计并调整伏立康唑抗真菌药物治疗方案。结果 2例经临床症状、体征、痰培养提示真菌（1例为曲霉菌、1例为热带念珠菌）并结合肺CT变化,确诊为肺真菌感染的患者;第3例为化疗后IV度骨髓抑制,出现粒细胞缺乏伴发热,经规范抗感染治疗效果欠佳,需经验给予抗真菌治疗的患者。3位患者均为伏立康唑相关基因CYP2C19超快代谢型,初始给予伏立康唑抗真菌治疗效果均欠佳（临床症状无改善,血药浓度不达标）,调整治疗方案增加伏立康唑单次给药剂量并联合应用奥美拉唑,抗真菌效果显著改善（伏立康唑血药谷浓度提升并达标,感染症状明显改善）,成功救治患者。结论 CYP2C19超快代谢型患者应用伏立康唑抗真菌治疗时,可通过奥美拉唑对伏立康唑代谢酶的竞争及抑制作用大幅增加伏立康唑血药浓度,既达到了提升伏立康唑抗真菌治疗效果的目的,又杜绝了药物调整过量所致不良反应发生的风险,为临床伏立康唑个体化治疗提供了新思路。

关键词: 伏立康唑, 奥美拉唑钠, 药物相互作用, 血药浓度监测, 药物代谢酶

Abstract: Objective To explore the role of voriconazole combined with omeprazole sodium in increasing the blood concentration of voriconazole and enhancing antifungal efficacy in patients with CYP2C19 ultrarapid metabolism. Methods The clinical data on three patients who had voriconazole-associated gene CYP2C19 with ultrarapid metabolizing invasive pulmonary mycosis was analyzed. The treatment with voriconazole was designed and adjusted based on monitoring results of blood concentrations. Results Two of the three patients were diagnosed with pulmonary mycosis based on clinical symptoms, signs, and sputum culture, suggesting fungal infection (one case with Aspergillus and one case with Candida tropicalis) combined with pulmonary CT changes. The third case was a patient with degree IV myelosuppression after chemotherapy, who had agranulocytosis and fever and needed to be treated with an empirical antifungal therapy due to the poor efficacy of a standardized anti-infective therapy. All the three patients had voriconazole-associated gene CYP2C19 with ultrarapid metabolism. The initial antifungal treatment with voriconazole was not effective (the clinical symptoms were not improved, and the blood concentration was not up to the standard). The treatment plan was adjusted by increasing the single dose of voriconazole and by combining voriconazole with omeprazole sodium so that the antifungal effect was significantly improved (the blood concentration of voriconazole increased and reached the standard, and the symptoms of infection were significantly improved), and the patients were cured. Conclusion When an antifungal therapy with voriconazole is used in patients with CYP2C19 ultrarapid metabolism, the blood concentration of voriconazole can be greatly increased via the competition and inhibitory effect of omeprazole on voriconazole metabolism enzymes. This approach can not only improve the antifungal effect of voriconazole, but also eliminate the risk of adverse reactions caused by excessive drug adjustment. It provides a new idea for clinical individualized treatment of voriconazole.

Key words: voriconazole, omeprazole sodium, drug interaction, blood concentration monitoring, drug metabolizing enzyme

中图分类号:

R994.11

连玉菲, 刘洪涛, 任炳楠, 赵海静, 王彦泽, 张玥, 田冬冬, 曹格溪, 岳圆圆, 闫莉. 伏立康唑与奥美拉唑联合应用致伏立康唑超快代谢型患者血药浓度增高的分析[J]. 中国药物警戒, 2020, 17(8): 496-501.

LIAN Yufei, LIU Hongtao, REN Bingnan, ZHAO Haijing, WANG Yanze, ZHANG Yue, TIAN Dongdong, CAO Gexi, YUE Yuanyuan, YAN Li. Blood Concentration of Voriconazole in Patients with Ultrarapid Metabolism Increased by Combination of Voriconazole and Omeprazole[J]. Chinese Journal of Pharmacovigilance, 2020, 17(8): 496-501.

参考文献

[1] 中国侵袭性真菌感染工作组.血液病/恶性肿瘤患者侵袭性真菌病的诊断标准与治疗原则( 第四次修订版)[J].中华内科杂志,2013,52( 8) : 704-709.
[2] Jeong S,Nguyen PD,Desta Z.Comprehensive in vitro analysis of voriconazole inhibition of eight cytochrome P450 (CYP) enzymes: major effect on CYPs 2B6,2C9,2C19,and3A[J].Antimicrobial agents and chemotherapy,2009,53( 2) : 541-551.
[3] Shin JM,Kim N.Pharmacokinetics and pharmacodynamics of the proton pump inhibitors[J].J Neurogastroenterol Motil,2013,19( 1) : 25-35.
[4] Gerd M,Iina Maria S,Johanna W.Pharmacogenomics of the triazole antifungal agent voriconazole[J].Pharmacog-enom-ics,2011,12( 6) : 861-872.
[5] 卜明华,张颖,刘建勋,等.细胞色素P450酶诱导/抑制的研究方法及在药物研究中的应用[J].中国临床药理学与治疗学,2011,16(5):579-585.
[6] Boyd NK,Zoellne RCL,Swancutt MA,et al.Utiliz ation of omeprazole to augment subtherapeutic voriconazole concentrations for treatment of Aspergillus infections[J].Antimicrob Agents Chemother,2012,56(11): 6001-6002.
[7] 陈恳,张相林,克晓燕,等.《伏立康唑个体化用药指南》解读[J].临床药物治疗志,2019,17(03):47-52+78.
[8] Kang HM,Lee HJ,Cho EY,et al.The clinical signifi-cance of voriconazole therapeutic drug monitoring in child-ren with invasive fungal infections[J].Pediatr Hematol Oncol,2015,32( 8) : 557–567.
[9] Chau MM,Kong DCM,Van Hal MJ,et al.Consen-sus guidelines for optimising antifungal drug deliveryand monitoring to avoid toxicity and improve outcomes inpatients with haemat-ological malignancy[J].Int Med J,2014,44(12B) : 1364-1388.
[10] Hyland R,Jones BC,Smith DA.Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole[J].Drug Metab Dispos,2003,31(5):540-547.
[11] Boyd NK,Zoellne RCL,SWANCUTT MA,et al.Utilization of omeprazole to augment subtherapeutic voriconazole concentrations for treatment of Aspergillus infections[J].Antimicrob Agents Chemother,2012,56( 11) : 6001-6002.
[12] Shin JM,Kim N.Pharmacokinetics and pharmacodynamics of the proton pump inhibitors[J].J Neurogastroenterol Motil,2013,19(1):25-35.
[13] Lee S,Kim B H,Nam W S,et al.Effect of CYP2C19 polymor-phism on the pharmacokinetics of voriconazole after single and multiple doses in healthy volunteers[J].J Clin Pharmacol,2012,52( 2) : 195-203.
[14] Sim SC,Risinger C,Dahl ML,et al.A common novel CYP2C19 genevariant causes ultra-rapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants[J].Clin Pharmacol Ther, 2006,79(1):103-113.
[15] Zdenek RACIL,Jana ANA WIinte ROVA,Michalr Kouba,et al.Monitoring troughvoriconazole plasma concentrations in haematologicalpatients: real life multicentreexperience[J].Mycoses,2012,55(5) : 483-492.
[16] 姜英杰,李瑜元,聂玉强,等.雷贝拉唑根除幽门螺杆菌疗效及其与 CYP2C19 基因多态性的关系[J].广州医学院学报,2004,32( 3) : 22-25.
[17] Matsumoto K,Ikawa K,Abematsu K,et al.Correlation between voriconazole trough plasma concentration and hepatotoxicity in patients with different CYP2C19 genotypes[J].Int J Antimicrob Agents,2009,34(1) : 91-94.
[18] 王瓅珏,唐惠林,段京莉,等.CYP2C19 基因多态性对伏立康唑药代动力学影响的系统评价[J].中国临床药理学杂志,2011,27(8) : 607-611.
[19] Pestka E L,Hale A M,Johnson B L,et al.Cytochrome P450 testing for better psychiatric care[J].J Psychosoc Nurs Ment Health Serv,2007,45(10) : 15-18.
[20] Prerna K,Chawla,Shweta R,et al.Correlation of CYP2C19 genotype with plasma voriconazole levels: a preliminary retros- pective study in Indians[J]. Int J Clin Pharm,2015,37:925-930.
[21] F abien Lamoureux, Thomas Duflot, Jean-Baptiste Woillard, et al.Impact of CYP2C19 genetic polymorphisms on voriconazole dosing and exposure in adult patients with invasive fungal infec- tions[J]. F. Lamoureux et al[J]. International Journal of Antimi-crobial Agents,2016,47:124-131.
[22] 邵贝贝,赵宁民,段虹飞等.基于基因多态性的伏立康唑药代动力学研究状况 [A]. 中国临床药理学杂志 ,2016,32(7):663-666.
[23] Pascual A,Calandra T,Bolay S,et al.Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes[J]. Clin Infect Dis,2008,46(2):201-211.
[24] Mitsanid,Nguyen MH,Shields RK,et al. Prospective,observational study of voriconazole therapeutic drug monitoring among lung transplant recipients receiving prophylaxis: factors impacting levels of and associations between serum troughs,efficacy,and toxicity[J]. Antimicrob Agents Chemother,2012,56(5) : 2371-2377.
[25] Dolton MJ,Ray JE,Chen SC,et al.Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring[J].Antimicrob Agents Chemother,2012,56(9):4793-4799.
[26] Park WB,Kim NH,Kim KH,et al.The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial[J].Clin Infect Dis,2012,55(8):1080-1087.
[27] 章袁,朱立勤,元芳,等.伏立康唑与奥美拉唑联合应用的药物间相互作用研究[J].中国新药杂志,2017,26(17):2097-2100.
[28] Fang H,Str Oms,Ellis E,et al.Positive and negative regulation of human hepatic hydroxysteroid sulf otransferase( SULT2A1) gene transcription by rifampicin : roles of hepatocyte nuclear factor 4 alpha and pregnane X receptor[J].J Pharmacol Exp Ther,2007,323(2):586-598.
[29] Wood N,Tan K,Purkins L,et al.Effect of omeprazole on the steady-state pharmacokinetics of voriconazole[J].Br J Clin Pharmacol,2003,56( Suppl 1) : 56-61.

伏立康唑与奥美拉唑联合应用致伏立康唑超快代谢型患者血药浓度增高的分析

Blood Concentration of Voriconazole in Patients with Ultrarapid Metabolism Increased by Combination of Voriconazole and Omeprazole

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	吕鹏, 张京莉, 王运红, 马芬芬, 张玉, 黄怡菲. 伏立康唑致肺移植受者皮肤鳞状细胞癌危险因素及机制研究进展[J]. 中国药物警戒, 2023, 20(5): 595-600.
[2]	胡碧原, 汪静, 郑微旗, 胡宏平, 陈泳伍. 注射用伏立康唑致自杀倾向与感觉异常1例分析[J]. 中国药物警戒, 2023, 20(4): 469-472.
[3]	张雯雯, 聂西庭, 徐会茹, 冉晔, 田成林, 于生元. 华法林片联合复方氨酚烷胺片致凝血功能极度异常1例分析[J]. 中国药物警戒, 2023, 20(11): 1290-1292.
[4]	谢婧, 关飞. 药物诱发髂腰臀肌自发性出血1例分析[J]. 中国药物警戒, 2023, 20(11): 1299-1302.
[5]	赵瑞, 于晓佳, 安卓玲. 1例大剂量胺碘酮诱发伊伐布雷定闪光现象的药学监护[J]. 中国药物警戒, 2023, 20(10): 1173-1175.
[6]	付小桐, 刘婷, 曹春雨, 张海静, 夏冰, 赵晓昂, 王丽芳, 赵春晖, 杨依霏. 基于P450酶的雷公藤多苷致大鼠肝损伤及其与复方甘草酸苷配伍减毒研究[J]. 中国药物警戒, 2023, 20(1): 85-91.
[7]	寻晓庆, 彭玲玲. 258例癫痫患儿丙戊酸钠的血药浓度监测及影响因素分析[J]. 中国药物警戒, 2022, 19(9): 1027-1029.
[8]	张茜, 李鹏飞, 赵杰, 刘丽宏. 162例注射用奥美拉唑钠不良反应报告分析[J]. 中国药物警戒, 2022, 19(3): 287-291.
[9]	曹鑫, 崔向丽. 移植患者伏立康唑对免疫抑制剂的浓度及临床结局影响[J]. 中国药物警戒, 2022, 19(2): 193-195.
[10]	张黎, 陈海涛, 陈学梁, 高秀蓉. 1例伏立康唑联合米卡芬净治疗慢性阻塞性肺疾病合并侵袭性肺曲霉菌感染患者的药学监护[J]. 中国药物警戒, 2022, 19(12): 1380-1383.
[11]	汪乐尘, 沈爱宗. 安徽省某三甲医院伏立康唑致低钾血症不良反应分析[J]. 中国药物警戒, 2022, 19(11): 1238-1241.
[12]	张晓娟, 杨宏昕, 郭小彬, 解沛涛. 伏立康唑片引起幻视和幻觉不良反应2例及相关文献回顾[J]. 中国药物警戒, 2021, 18(6): 588-591.
[13]	曹鑫, 孙玉泉, 黄贵民, 冉仲阳, 崔向丽. 他克莫司与伏立康唑联合使用不良反应信号挖掘与分析[J]. 中国药物警戒, 2021, 18(5): 483-488.
[14]	张泰, 王岩艳. 药用辅料影响诊疗安全研究进展[J]. 中国药物警戒, 2021, 18(5): 492-494.
[15]	吕锦涛, 张丹, 张冰, 萨日娜, 林志健, 张晓朦. 柑橘属中药的药物相互作用研究进展[J]. 中国药物警戒, 2021, 18(5): 495-498.